{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:00:49Z","timestamp":1791234049751,"version":"4.1.0"},"reference-count":34,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Discipline Cluster of Oncology, Wenzhou Medical University, China","award":["z1-2023003"],"award-info":[{"award-number":["z1-2023003"]}]},{"name":"National Health Commission Pharmaceutical Health Science and Technology Development Research Center of innovative drug post-marketing clinical research project","award":["WKZX2024CX104301"],"award-info":[{"award-number":["WKZX2024CX104301"]}]},{"name":"Zhejiang Province Medical and health science and Technology project","award":["2024KY141"],"award-info":[{"award-number":["2024KY141"]}]},{"name":"Clinical and basic research project of Beijing Kangmeng Charity Foundation Medical Research and Development Fund","award":["CB23005"],"award-info":[{"award-number":["CB23005"]}]},{"DOI":"10.13039\/501100019542","name":"Basic Research Project of Wenzhou City","doi-asserted-by":"publisher","award":["2024Y0284"],"award-info":[{"award-number":["2024Y0284"]}],"id":[{"id":"10.13039\/501100019542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019542","name":"Basic Research Project of Wenzhou City","doi-asserted-by":"publisher","award":["Y20220186"],"award-info":[{"award-number":["Y20220186"]}],"id":[{"id":"10.13039\/501100019542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019542","name":"Basic Research Project of Wenzhou City","doi-asserted-by":"publisher","award":["Y20220694"],"award-info":[{"award-number":["Y20220694"]}],"id":[{"id":"10.13039\/501100019542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,4,17]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This trial investigates the efficacy of neoadjuvant therapy using rezvilutamide combined with androgen deprivation therapy (ADT), with or without docetaxel, in treating oligometastatic hormone-sensitive prostate cancer (omHSPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This prospective, open-label, multicentre trial aims to enrol 100 patients newly diagnosed with omHSPC (defined as \u22645 bone or lymph node metastases confirmed by conventional imaging, without visceral metastasis) who must express a desire to undergo surgery. All patients undergo a prostate-specific membrane antigen positron emission tomography\/CT (PSMA-PET\/CT) scan at enrolment or within 4 weeks before enrolment to assess and confirm the number of metastases at baseline. Scans should be performed before initiating ADT to avoid compromising test sensitivity. Then patients will be allocated into groups in parallel according to their own preferences: one group will receive an LHRH agonist or antagonist for 24 weeks to maintain continuous ADT or have undergone bilateral orchiectomy. Treatment with rezvilutamide will be maintained daily. The other group will be scheduled to complete up to six cycles of docetaxel within 24 weeks, with maintenance of continuous ADT and rezvilutamide for 24 weeks. Both groups will receive a conventional imaging evaluation at the 12th week. After neoadjuvant therapy, patients will undergo conventional imaging and a second PSMA-PET\/CT assessment, followed by cytoreductive radical prostatectomy within the subsequent 6 weeks. After surgery, patients may choose to continue with ADT or rezvilutamide at their own discretion, until disease progression. The primary endpoint is pathological complete response, defined as the absence of residual viable tumour cells in the tumour bed on pathological evaluation of the postoperative specimen. Secondary endpoints include 1 year biochemical progression-free survival, overall survival, radiographic progression-free survival, time to prostate-specific antigen progression, quality of life scores (total and subscale) assessed using the Functional Assessment of Cancer Therapy-Prostate questionnaire, time to symptomatic progression, time to deterioration in Eastern Cooperative Oncology Group performance status, the interval from enrolment to an increase in score from baseline, the proportion of patients with a \u226530% reduction in prostate volume on imaging before cytoreductive surgery compared with pre-neoadjuvant therapy, minimal residual disease and major pathological response. The study plans to enrol a total of 100 patients. Patient recruitment for this study is scheduled to begin in May 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This has been approved by the Ethics Committee in Clinical Research of the First Affiliated Hospital of Wenzhou Medical University (number KY2024-231). Results will be published in peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study is expected to provide prospective evidence on the feasibility and potential clinical value of rezvilutamide combined with ADT, with or without docetaxel, as neoadjuvant treatment for newly diagnosed omHSPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry (ChiCTR2400093262).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-110503","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:25:52Z","timestamp":1778599552000},"page":"e110503","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Rezvilutamide in combination with androgen deprivation therapy (ADT) with or without docetaxel in the neoadjuvant treatment of oligometastatic prostate cancer (REDOOM): study protocol for an open-label, parallel-cohort, multicentre clinical study"],"prefix":"10.1136","volume":"16","author":[{"given":"Zi-Jian","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6712-6575","authenticated-orcid":false,"given":"Xin-Xu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Zhe","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Di","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Wound Repair, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Affiliated Hospital and Yuying Children\u2019s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-De","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Xian","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Te","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"},{"name":"Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wei","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"2026062608320752000_16.5.e110503.1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1"},{"key":"2026062608320752000_16.5.e110503.2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20240119-00035"},{"key":"2026062608320752000_16.5.e110503.3","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2016.30"},{"key":"2026062608320752000_16.5.e110503.4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/cac2.12197","article-title":"Cancer incidence, mortality, and burden in China: a time\u2010trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020","volume":"41","author":"Qiu","year":"2021","journal-title":"Cancer Commun"},{"key":"2026062608320752000_16.5.e110503.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00799"},{"key":"2026062608320752000_16.5.e110503.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903835"},{"key":"2026062608320752000_16.5.e110503.7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"key":"2026062608320752000_16.5.e110503.8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JU.0000000000004163","article-title":"Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP)","volume":"212","author":"Shore","year":"2024","journal-title":"J Urol"},{"key":"2026062608320752000_16.5.e110503.9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41391-020-0254-y","article-title":"Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis","volume":"24","author":"Yuan","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026062608320752000_16.5.e110503.10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/JU.0000000000003876","article-title":"A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy","volume":"211","author":"Qian","year":"2024","journal-title":"J Urol"},{"key":"2026062608320752000_16.5.e110503.11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.prnil.2020.12.003","article-title":"Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer","volume":"9","author":"Preisser","year":"2021","journal-title":"Prostate Int"},{"key":"2026062608320752000_16.5.e110503.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263124"},{"key":"2026062608320752000_16.5.e110503.13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026062608320752000_16.5.e110503.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4853"},{"key":"2026062608320752000_16.5.e110503.15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026062608320752000_16.5.e110503.16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/07357907.2017.1375116","article-title":"11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer","volume":"35","author":"Franzese","year":"2017","journal-title":"Cancer Invest"},{"key":"2026062608320752000_16.5.e110503.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)01442-1"},{"key":"2026062608320752000_16.5.e110503.18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s00066-020-01660-6","article-title":"Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET\/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)","volume":"196","author":"Hurmuz","year":"2020","journal-title":"Strahlenther Onkol"},{"key":"2026062608320752000_16.5.e110503.19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ijc.32509","article-title":"Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial","volume":"146","author":"Bowden","year":"2020","journal-title":"Int J Cancer"},{"key":"2026062608320752000_16.5.e110503.20","article-title":"Outcomes after a first and\/or second salvage treatment in patients with oligometastatic prostate cancer recurrence detected by (18\u2010F) choline PET\u2010CT","volume":"28","author":"Gomez\u2010Iturriaga","year":"2019","journal-title":"Eur J Cancer Care"},{"key":"2026062608320752000_16.5.e110503.21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092313","article-title":"Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone","volume":"14","author":"Mistretta","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026062608320752000_16.5.e110503.22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00259-020-04777-z","article-title":"Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer","volume":"48","author":"Stefan","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026062608320752000_16.5.e110503.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.11.008"},{"key":"2026062608320752000_16.5.e110503.24","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00259-021-05636-1","article-title":"Dual-tracer PET\/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study","volume":"49","author":"Qiu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026062608320752000_16.5.e110503.25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.02.003","article-title":"Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review","volume":"4","author":"Farolfi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2026062608320752000_16.5.e110503.26","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00345-019-02950-0","article-title":"Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H","volume":"38","author":"Knipper","year":"2020","journal-title":"World J Urol"},{"key":"2026062608320752000_16.5.e110503.27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","article-title":"Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer: A Phase II Randomized Controlled Trial","volume":"5","author":"Dai","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2026062608320752000_16.5.e110503.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.012"},{"key":"2026062608320752000_16.5.e110503.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.02.084"},{"key":"2026062608320752000_16.5.e110503.30","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bju.15055","article-title":"The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer","volume":"125","author":"Ranasinghe","year":"2020","journal-title":"BJU Int"},{"key":"2026062608320752000_16.5.e110503.31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","article-title":"Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"2026062608320752000_16.5.e110503.32","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume":"23","author":"Gu","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026062608320752000_16.5.e110503.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.07.010"},{"key":"2026062608320752000_16.5.e110503.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303974"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-110503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:43:56Z","timestamp":1782488636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-110503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjopen-2025-110503"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-110503","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}